Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at the ACT 43rd Annual Meeting

2022-11-04
|
Page View:

It is our pleasure to share the following information with you: ACT 43rd Annual Meeting kicks off on November 13, 2022 at the Gaylord Rockies located outside Denver, Colorado. Maybe we can work together and Medicilon can be a great partner! Come and chat with our American team at booth No. 303!


About ACT 43rd Annual Meeting

ACT is a global community of professional scientists representing the pharmaceutical and biotech industries, regulatory agencies, contract research organizations, academia, and consulting firms. The mission of the College is to educate, lead, and serve scientists by promoting an exchange of information and perspectives on safety assessment and new developments related to applied toxicology. The Annual Meeting is the heart of ACT. This November gathering brings together a community of toxicologists at small venues conducive to idea exchange, professional networking, and continuing education. First-rate Scientific Sessions are member-driven, pharma-focused (though not pharma exclusive), and organized to maximize learning opportunities with distinguished plenary speakers, the popular Poster Session, an Awards Ceremony, and several professional networking events.

 

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

 

Medicilon Drug Discovery Services

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

 

Medicilon Pharmacology & Toxicology Services

We boast professional teams and practical experience in drug safety evaluation and can promise high-quality data and fast turnaround time to support various drug safety evaluation. Our toxicology research can be carried out according to non-GLP or GLP standards. Our research platform has been rated as Shanghai R&D Public Service Platform.

 

Services:

Genetic toxicity tests

Immunogenicity tests

Toxicokinetic tests

ADC safety evaluation

Local toxicity tests (hemolysis, allergy and irritation tests)

 

 

Our advantages:

Medicilon has cooperated with MPI and followed MPI's quality management system/SOP;

Medicilon features comprehensive quality control measures three-level QC management mode;

Medicilon has a comprehensive data management software system;

Medicilon features qualities like AAALAC Accreditation and GLP certificate by NMPA, and has passed the on-site inspection by FDA


Share:
Return
Relevant newsRelevant news